U.S. markets close in 3 hours 41 minutes
  • S&P 500

    4,248.81
    +41.54 (+0.99%)
     
  • Dow 30

    33,584.16
    +247.49 (+0.74%)
     
  • Nasdaq

    12,949.15
    +169.24 (+1.32%)
     
  • Russell 2000

    1,999.89
    +24.63 (+1.25%)
     
  • Crude Oil

    92.08
    -2.26 (-2.40%)
     
  • Gold

    1,812.00
    +4.80 (+0.27%)
     
  • Silver

    20.51
    +0.16 (+0.79%)
     
  • EUR/USD

    1.0259
    -0.0067 (-0.65%)
     
  • 10-Yr Bond

    2.8690
    -0.0190 (-0.66%)
     
  • GBP/USD

    1.2133
    -0.0069 (-0.57%)
     
  • USD/JPY

    133.5090
    +0.5100 (+0.38%)
     
  • BTC-USD

    24,031.25
    -302.29 (-1.24%)
     
  • CMC Crypto 200

    570.95
    -0.33 (-0.06%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia.

  • The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.

  • The results were highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress.

  • IMC‑1 exhibited an encouraging safety profile, as adverse events occurred at a lower rate and were less severe in the IMC‑1 treatment group compared with placebo.

  • The discontinuation rate was nearly 3‑fold higher in patients receiving placebo than the IMC‑1 group, suggesting that treatment with IMC‑1 was unusually well‑tolerated.

  • Significant reductions in pain, fatigue, and other vital symptoms were observed.

  • Price Action: VIRI shares are up 12.1% at $6.30 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.